Every patient begins with a consultation with Dr. Heather Volpp, MD. Your full clinical picture is reviewed before any protocol is designed.
SynergyO3 identifies upstream biological drivers — oxidative stress, toxin burden, immune dysregulation, pathogen load — rather than treating symptoms in isolation.
EBOO, HOCATT®, IV therapy, and regenerative biologics work as a system — addressing multiple physiological drivers simultaneously for compounding outcomes.
Lyme disease, caused by Borrelia burgdorferi and transmitted by Ixodes ticks, is increasingly understood as a multi-system disease — not simply an infection that antibiotics resolve. In many patients, especially those diagnosed late, symptoms persist for months or years despite standard antibiotic treatment.
Chronic or persistent Lyme involves multiple interacting mechanisms: ongoing pathogen burden, immune dysregulation, neurotoxin accumulation, mitochondrial dysfunction, and the co-infection burden of Bartonella, Babesia, Ehrlichia, and others — each requiring separate attention.
Dr. Volpp evaluates the full tick-borne illness picture, including comprehensive co-infection testing, immune function markers, and toxin burden — then builds a multi-system protocol designed to address each driver rather than the infection alone.
The same tick bite that transmits Borrelia commonly transmits co-infections including Bartonella, Babesia, Ehrlichia, and Anaplasma — each requiring targeted attention. A Lyme-only treatment plan often fails because co-infections are missed or untreated.
Book Consultation →Standard antibiotic protocols address the bacterial infection but do nothing to resolve the immune dysregulation, neurotoxin burden, mitochondrial dysfunction, and co-infection load that perpetuate chronic symptoms.
Many Lyme patients carry Bartonella, Babesia, or other co-infections that require different treatment approaches. A Lyme-focused plan that ignores co-infections leaves key drivers of disease unaddressed.
Borrelia and co-infections produce significant neurotoxin burden. Standard care rarely addresses toxin elimination directly, leaving biotoxins to accumulate and drive ongoing symptoms.
Extra-corporeal Blood Ozone and Oxygenation (EBOO) is a closed-circuit medical procedure that ozonates your blood outside the body — driving systemic physiological changes targeted at the specific mechanisms driving your condition.
Ozone is directly bactericidal against Borrelia burgdorferi and many common co-infection organisms. EBOO delivers ozonated blood systemically, reaching pathogen reservoirs that oral antibiotics struggle to access.
Ozone oxidizes circulating biotoxins and supports hepatic detoxification pathways — addressing the neurotoxin accumulation that drives cognitive, neurological, and inflammatory symptoms.
Chronic Lyme creates complex immune dysregulation. EBOO's immunomodulatory effects help recalibrate immune response toward appropriate pathogen clearance.
Borrelia disrupts cellular energy production. EBOO enhances oxygen utilization and ATP synthesis, addressing the profound fatigue and cognitive dysfunction that mark chronic Lyme disease.
HOCATT®'s combined transdermal ozone, far-infrared heat, and carbonic acid create powerful synergies for Lyme patients. The thermal component induces a controlled fever-like response — historically recognized as beneficial for Borrelia, which is heat-sensitive. Far-infrared supports lymphatic drainage of biotoxins. Carbonic acid improves tissue oxygenation in areas of poor perfusion where Borrelia can sequester.
Ask About HOCATT® →Ozone absorbed through skin delivers anti-inflammatory effects without the intensity of systemic EBOO.
Deep tissue heating supports detoxification, reduces musculoskeletal pain, and stimulates mitochondrial activity.
CO2 dissolved in steam causes potent vasodilation — improving peripheral circulation and oxygen delivery.
Completely non-invasive. Patients sit reclined inside the HOCATT® pod. No needles, no downtime.
Ozone has documented in vitro bactericidal activity against Borrelia burgdorferi. EBOO delivers ozonated blood systemically, reaching the bloodstream and tissues. It is used as part of a multi-modal approach.
In most cases, yes — and the combination may be synergistic. Dr. Volpp reviews your current antibiotic protocol and determines appropriate timing at consultation.
Acute Lyme responds well to standard antibiotic protocols when caught early. Chronic Lyme involves multiple systems and requires a multi-modal approach addressing immune dysregulation, toxin burden, co-infections, and cellular dysfunction.
CD57 is a subset of natural killer cells that is frequently depleted in chronic Lyme disease. Low CD57 is associated with more severe illness and slower recovery. SynergyO3 monitors CD57 as a marker of immune recovery.
Lyme typically requires 8-12 sessions in the first 3 months, then maintenance. Recovery is a multi-month process given the complexity of the disease burden.
Yes. Comprehensive co-infection testing is part of the initial evaluation. Treatment protocols are designed around the full tick-borne illness picture, not Lyme alone.
Herxheimer (die-off) reactions can occur when pathogen burden decreases rapidly. Dr. Volpp anticipates this and includes supportive protocols to minimize Herx intensity during treatment.
Insurance is not accepted. Superbills for HSA/FSA reimbursement are provided. Written pricing is given before all services.
Before any treatment begins, Dr. Volpp reviews your complete health history, labs, and goals. Every protocol is physician-designed for your specific biology — not a template.
Book Your Consultation →(760) 450-4602 · info@synergyo3.com · Mon-Fri 9:00am-5:00pm
Insurance not accepted · HSA/FSA superbills available · Written quotes before all services